Andy Batts
Long only, value, growth, momentum

Cardiovascular Systems' Orbital Atherectomy Could Be A Game Changer

Cardiovascular Systems (NASDAQ:CSII) has designed its Diamondback 360 device for removing arterial calcium buildups in vessels before stenting. The FDA approved the device for the treatment of leg and heart vessels in 2007, but later last year the agency cleared the device for calcified coronary arteries, a $1.5 billion market dominated by last generation technologies, according to CSII CEO David Martin. He further said:

FDA approval of our Diamondback 360 Coronary OAS allows us to bring to market the first new coronary atherectomy system in more than two decades. Severe coronary arterial calcium is an underestimated problem in medicine, with limited options for treatment.

Estimated Valuation

The opportunity is huge and I believe this could eventually turn...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details